Unique series of workshops in partnership with the European Medicines Agency (EMA)

In a significant stride towards advancing cancer research and drug development, the European Organisation for Research and Treatment of Cancer (EORTC) has joined forces with the European Medicines Agency (EMA) in a groundbreaking collaboration. This strategic partnership aims to foster innovation, streamline processes, and accelerate the translation of scientific discoveries into effective cancer treatments.

The first half of 2024 will see an extraordinary series of workshops where EORTC and EMA will work hand in hand to address the many challenges of clinical research: from ultra-rare cancers to quality of life and treatment optimisation.

By fostering synergies between academic research and regulatory processes, this partnership aims to accelerate the delivery of new and effective cancer treatments to patients across the European Union.

  • The EMA/EORTC multi-stakeholder workshop on soft tissue and bone sarcoma took place in hybrid mode on 12 January 2024 in Amsterdam, Netherlands. More information here.

  • The joint EMA/EORTC Workshop titled “How can patient-reported outcomes (PRO) and health-related quality of life (HRQoL) data inform regulatory decisions?” will take place in hybrid mode on 29 February 2024 in Amsterdam, Netherlands. Register here.

  • The Cancer Medicines Forum workshop will take place in hybrid mode on 5 April 2024 in Amsterdam, Netherlands. Register here.

Denis Lacombe, EORTC CEO expressed immense enthusiasm about this series of workshops: “This unique collaboration is a remarkable testament to the shared commitment of EORTC and EMA to advancing cancer research. By combining our expertise, we aim to overcome hurdles and accelerate the development of innovative and effective therapies for the benefit of patients.”

The collaborative efforts of EORTC and EMA are expected to pave the way for a more harmonised and efficient landscape in cancer research and drug development, offering renewed hope for patients and further establishing Europe as a leader in the global fight against cancer.

Back to news list

Related News

  • We are pleased to announce the release of the EORTC 2023 Annual Report

  • Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023